Starting and conducting clinical trials in England can be a complicated and time-consuming process.
Introduction
Prior to starting a clinical trial it is necessary to gain approval from the relevant regulatory bodies. Regulatory bodies have a legal responsibility to approve, license or inspect particular research activities. They provide approval at a study-wide level. Such approvals for example can come from a Research Ethics Committee (REC), the Medicines and Healthcare products Regulatory Agency (MHRA), and the Administration of Radioactive Substances Advisory Committee. Prior to March 2016, National Health Service (NHS) permission (also known as Research and Development (R&D) approval) was required from the NHS host organisation through their R&D team. Approval was given at a site level by the NHS organisation with a duty of care to the patients or staff that would be recruited to the study at that site. In England, R&D approval was gained via the National Institute for Health Research (NIHR) Coordinated System for gaining NHS Permission (CSP). Gradually, since May 2015, this process has been overhauled and streamlined. A new system of Health Research Authority (HRA) approval has been introduced, with full implementation completed at the end of March 2016. 1 All new studies must now apply for HRA approval, as must amendments for already approved studies. This article will focus on the process of applying for HRA approval.
What is HRA approval?
The HRA is a part of the Department of Health in the UK. It exists to provide a unified national system for the governance of health research. If your study is led from England and involves the NHS you will need HRA approval for your study to start. It brings together the assessment of governance and legal compliance, and is undertaken by specialist HRA staff. An independent REC opinion will be provided in parallel through the UK Health Department's Research Ethics Service. HRA approval replaces the old system of needing NHS permission from each participating organisation. The aim of the new system is to simplify the process of approval for researchers, thus reducing the time and cost of setting up studies. It is hoped it will enable researchers to focus on their ability to deliver the study rather than being swamped by regulatory approvals. 2 HRA approval applies only to the NHS in England. Studies led from sites outside England (e.g. Wales or Scotland) will be supported through existing UK-wide compatibility systems. For cross-border studies the HRA shares the outcome of HRA approval with devolved nations' coordinating bodies, which will then conduct additional nation-specific checks.
When did the change happen?
The phased roll out began in May 2015 and was completed at the end of March 2016. HRA approval is now the only process in England for applying and approving all project-based research in the NHS led from England. Studies which have already applied for REC review but have not applied for R&D review (or need to add new NHS sites in England or have new amendments) will need to follow the HRA approval process. The old system using the NIHR CSP has now closed to new submissions and amendments.
What are the steps to gain HRA approval? 1 . Prepare a draft application.
Set up your research project in the online Integrated
Research Application System (IRAS). Ensure you complete all the sections and upload all the necessary documents. There is now a combined REC and R&D form and a combined checklist of documents. Ensure your patient information sheet and consent form are updated to include your IRAS project identification number (IRAS ID). 3. Obtain electronic authorisations from the necessary individuals involved in the trial through IRAS. 4. Call the Central Booking Service to book an application for HRA approval. You will be asked if you want your study to be reviewed by a NHS REC. You are still able to request review by a specific REC, however this may delay your application depending on availability of meeting slots. 3 5. E-submit your application via IRAS. 6. Once the application is received there will be an initial assessment alongside REC validation. This will be followed by HRA assessment and REC review. 7. Once a favourable opinion from the REC is received, the HRA will collate all approvals and you will then receive HRA approval for your study to start. HRA approval cannot be issued until the REC favourable opinion is in place. The HRA expects that studies applying for HRA approval will be ready to start promptly once approval is issued, so ensure you have everything in place to start recruitment.
All amendments must be submitted to the HRA. Figure 1 provides a summary of the process.
Top tips for successfully submitting your application
• • Start early -it is likely to take longer than you might think. 
Where to go for help
Research support staff are available in each local NHS trust to answer queries from local investigators. The IRAS website (www.myresearchproject.org.uk) has an e-learning module which can help guide you through the process of completing the IRAS application, and the HRA website can provide further links on where to find key guidance (www.hra.nhs.uk).
Future changes
The process for gaining approval is regularly amended, and HRA approval is expected to continue to develop further. It is therefore important to check with your local clinical trials and research governance team, or the HRA website for any further changes. 
